Ioannis G. Baraboutis

Ioannis G. Baraboutis

Auto-generated profile, based on publicly available information

Ioannis G. Baraboutis

Internal Medicine Clinic, Pammakaristos Hospital of Divine Providence (Reference Centre for COVID-19 Infection), Athens, Greece

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2010 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
IBI. G. Baraboutis
I. G. Baraboutis
ETE. P. Tsagalou
E. P. Tsagalou
JLJ. L. Lepinski
J. L. Lepinski
IPIlias P Papakonstantinou
Ilias P Papakonstantinou
VPV. Papastamopoulos
V. Papastamopoulos
SJS. Johnson
S. Johnson

4 April 2008
Verified
Journal Article
Closed access
EMEleni Mylona
Eleni Mylona
IBIoannis G Baraboutis
Ioannis G Baraboutis
LLLazaros J Lekakis
Lazaros J Lekakis
OGOurania Georgiou
Ourania Georgiou
VPVasilios Papastamopoulos
Vasilios Papastamopoulos
ASAthanasios Skoutelis
Athanasios Skoutelis

29 June 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
OVOdyssefs Violetis
Odyssefs Violetis
ACAngeliki Chasouraki
Angeliki Chasouraki
AGAlexandra M. Giannou
Alexandra M. Giannou
IBIoannis G. Baraboutis
Ioannis G. Baraboutis
The unfolding COVID-19 pandemic began in December 2019 in Wuhan, Hubei Province. COVID-19 is a systemic infection affecting several systems including the haematopoietic system. Surveys illustrating the laboratory findings of these patients conclude that lymphocytopenia, neutrophilia and thrombocytopenia are prominent amongst them. Moreover, it has been reported a significant decrease in T lymphocyte subsets and an increase of inflammatory cytokines of hospitalized patients with COVID-19. Generally, thrombocytopenia is commonplace in critically ill patients and usually suggests serious organ malfunction. In view of this, this review investigates the correlation between these abnormalities and the prognosis and disease course. Full blood count is an easy, economic and widely available tool which may help to discriminate between patients with or without severe disease. Last but not least, this review examines potential pathophysiological mechanisms by the novel coronavirus which contribute to these haematological alterations aiding the clinicians to better understand this disease and provide more clinical treatment options.

26 May 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
COCollaborators
Collaborators
IBIoannis G. Baraboutis
Ioannis G. Baraboutis
PGPanagiotis Gargalianos
Panagiotis Gargalianos
EAEleni Aggelonidou
Eleni Aggelonidou
AAAndreas Adraktas
Andreas Adraktas
We report our initial experience with the management of a mixed group of patients with COVID-19 infection, admitted and treated in a designated COVID-19 centre in the Athens Metropolitan area over a 4-week period. The SARS-CoV-2 pandemic presented a huge challenge to the Greek National Healthcare System and healthcare workers. Their response so far has been miraculously effective. Since there are essentially no therapeutic guidelines yet for this disease, we relied mainly on our medical intuition, our empathy for our patients and team work to do the best possible for 49 people with this infection. We present the therapeutic algorithm we gradually developed (on the job) and applied in our patients, based on continuous creative brainstorming and monitoring of the literature.

5 January 2021 in In Vivo
Verified
Journal Article
Open access
PDF file
GPGaryphallia Poulakou
Garyphallia Poulakou
EDEvangelos Dimakakos
Evangelos Dimakakos
AKAnastasios Kollias
Anastasios Kollias
KKKonstantinos G Kyriakoulis
Konstantinos G Kyriakoulis
VRVasiliki Rapti
Vasiliki Rapti
KSKonstantinos N. Syrigos
Konstantinos N. Syrigos
Background/Aim: To investigate the efficacy (prognosis, coagulation/inflammation biomarkers) and safety (bleeding events) of different anticoagulation dosages in COVID-19 inpatients. Patients and Methods: COVID-19 inpatients (Athens, Greece) were included. The “Enhanced dose THRomboprophylaxis in Admissions (ETHRA)” protocol was applied in certain Departments, suggesting the use of intermediate anticoagulation dosage. The primary endpoint was a composite of intubation/venous thromboembolism/death. Inflammation/coagulation parameters were assessed. Results: Among 127 admissions, 95 fulfilled the inclusion criteria. Twenty-one events (4 deaths, 17 intubations) were observed. Regression analysis demonstrated significant reduction of events with intermediate or therapeutic dosage [HR=0.16 (95%CI=0.05-0.52) p=0.002; HR=0.17 (0.04-0.71) p=0.015, respectively]. D-Dimer values were higher in those who met the composite endpoint. Intermediate dosage treatment was associated with decreased values of ferritin. Three patients (3%) had minor hemorrhagic complications. Conclusion: Anticoagulation treatment (particularly intermediate dosage) appears to have positive impact on COVID-19 inpatients’ prognosis by inhibiting both coagulation and inflammatory cascades.

1 June 2008 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
IBIoannis G. Baraboutis
Ioannis G. Baraboutis
AAAthena Argyropoulou
Athena Argyropoulou
VPVasilios Papastamopoulos
Vasilios Papastamopoulos
ZPZoi Psaroudaki
Zoi Psaroudaki
OPOlga Paniara
Olga Paniara
ASAthanasios T. Skoutelis
Athanasios T. Skoutelis
A 51 year old woman without significant past medical history or risk factors for Nocardia infection developed primary Nocardia nova sternal osteomyelitis with mediastinal abscess, diagnosed with open biopsy. She required prolonged antibiotic therapy and had a favorable outcome. Primary sternal osteomyelitis develops in the absence of a contiguous focus of infection, as opposed to secondary sternal osteomyelitis, which is usually a complication of sternotomy. Staphylococcus aureus probably still is the most common cause of both forms of sternal osteomyelitis. Nocardia species invade humans usually through the respiratory tract and can cause a variety of localized infections through the hematogenous route. Pulmonary involvement may or may not coexist. Immunosuppressed patients are more prone to infection by Nocardia species, although cases involving seemingly immunocompetent patients are not rare. This is the first reported case in the English literature of primary sternal osteomyelitis due to Nocardia nova or any other Nocardia species.